MODULATING GLUTEN-TRIGGERED IMMUNITY: THE NEXT STEP IN CELIAC DISEASE TREATMENT
Abstract
Celiac disease (CeD) is an autoimmune condition triggered by gluten ingestion in genetically predisposed individuals. Although a strict gluten-free diet (GFD) remains the gold standard for treatment, many patients experience ongoing symptoms or fail to achieve mucosal healing due to inadvertent gluten exposure and challenges in long-term adherence. These limitations and growing understanding of the pathophysiology of CeD have prompted the development of non-dietary therapies that target the underlying immune mechanisms of CeD. Emerging therapeutic strategies aim to modulate gluten-triggered immunity, including the inhibition of tissue transglutaminase 2 (TG2), blockade of HLA-DQ2.5 and gluten peptide complexes, suppression of interleukin-15 (IL-15), and interference with gut-homing lymphocyte trafficking. Among these, the TG2 inhibitor ZED1227 has demonstrated the most advanced clinical efficacy, while IL-15–targeting agents such as AMG 714 and CALY-002 show promise, particularly in refractory CeD. However, to date, none of those novel immune-modulating strategies have yet demonstrated sufficient efficacy and safety to replace dietary therapy. Therefore, future well-designed, long-term studies are needed to validate the efficacy, safety, and cost-effectiveness of immune-mediated therapies and to define their role in personalized management of CeD.
References
Amgen. (2025). A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease (Clinical Trial Registration NCT00540657). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT00540657
Barratt, S. M., Leeds, J. S., & Sanders, D. S. (2011). Quality of Life in Coeliac Disease is Determined by Perceived Degree of Difficulty Adhering to a Gluten-Free Diet, not the Level of Dietary Adherence Ultimately Achieved. Journal of Gastrointestinal and Liver Diseases, 20(3), Article 3.
Bodd, M., Ráki, M., Tollefsen, S., Fallang, L. E., Bergseng, E., Lundin, K. E. A., & Sollid, L. M. (2010). HLA-DQ2-restricted gluten-reactive T cells produce IL-21 but not IL-17 or IL-22. Mucosal Immunology, 3(6), 594–601. https://doi.org/10.1038/mi.2010.36
Cellier, C., Bouma, G., Gils, T. van, Khater, S., Malamut, G., Crespo, L., Collin, P., Green, P. H. R., Crowe, S. E., Tsuji, W., Butz, E., Cerf-Bensussan, N., Macintyre, E., Parnes, J. R., Leon, F., Hermine, O., Mulder, C. J., Jabri, B., Murray, J., … Raymond, R. (2019). Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: A phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. The Lancet Gastroenterology & Hepatology, 4(12), 960–970. https://doi.org/10.1016/S2468-1253(19)30265-1
Cenni, S., Casertano, M., D’Addio, E., Pacella, D., Tolone, C., Martinelli, M., Staiano, A., Miele, E., & Strisciuglio, C. (2025). Testing for Faecal Gluten Immunogenic Peptides: Is It Useful to Evaluate Adherence to Gluten-Free Diet? Acta Paediatrica. https://doi.org/10.1111/apa.70187
Ciccocioppo, R., Kruzliak, P., Cangemi, G. C., Pohanka, M., Betti, E., Lauret, E., & Rodrigo, L. (2015). The Spectrum of Differences between Childhood and Adulthood Celiac Disease. Nutrients, 7(10), 8733–8751. https://doi.org/10.3390/nu7105426
Comino, I., Fernández-Bañares, F., Esteve, M., Ortigosa, L., Castillejo, G., Fambuena, B., Ribes-Koninckx, C., Sierra, C., Rodríguez-Herrera, A., Salazar, J. C., Caunedo, Á., Marugán-Miguelsanz, J. M., Garrote, J. A., Vivas, S., lo Iacono, O., Nuñez, A., Vaquero, L., Vegas, A. M., Crespo, L., … Sousa, C. (2016). Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients. The American Journal of Gastroenterology, 111(10), 1456–1465. https://doi.org/10.1038/ajg.2016.439
De Re, V., Magris, R., & Cannizzaro, R. (2017). New Insights into the Pathogenesis of Celiac Disease. Frontiers in Medicine, 4, 137. https://doi.org/10.3389/fmed.2017.00137
Dotsenko, V., Tewes, B., Hils, M., Pasternack, R., Isola, J., Taavela, J., Popp, A., Sarin, J., Huhtala, H., Hiltunen, P., Zimmermann, T., Mohrbacher, R., Greinwald, R., Lundin, K. E. A., Schuppan, D., Mäki, M., & Viiri, K. (2024). Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease. Nature Immunology, 25(7), 1218–1230. https://doi.org/10.1038/s41590-024-01867-0
Elli, L., Leffler, D., Cellier, C., Lebwohl, B., Ciacci, C., Schumann, M., Lundin, K. E. A., Chetcuti Zammit, S., Sidhu, R., Roncoroni, L., Bai, J. C., Lee, A. R., Dennis, M., Robert, M. E., Rostami, K., Khater, S., Comino, I., Cebolla, A., Branchi, F., … Sanders, D. S. (2024). Guidelines for best practices in monitoring established coeliac disease in adult patients. Nature Reviews Gastroenterology & Hepatology, 21(3), 198–215. https://doi.org/10.1038/s41575-023-00872-2
Fernandez-Becker, N. (2022). A Phase 1b Study of PTG-100 in Patients With Celiac Disease (Clinical Trial Registration NCT04524221). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT04524221
Hall, N. J., Rubin, G., & Charnock, A. (2009). Systematic review: Adherence to a gluten-free diet in adult patients with coeliac disease. Alimentary Pharmacology & Therapeutics, 30(4), 315–330. https://doi.org/10.1111/j.1365-2036.2009.04053.x
Hardy, M. Y., Henneken, L. M., Russell, A. K., Okura, Y., Mizoroki, A., Ozono, Y., Kobayashi, S., Murakami, Y., & Tye-Din, J. A. (2024). A bispecific antibody targeting HLA-DQ2.5-gluten peptides potently blocks gluten-specific T cells induced by gluten ingestion in patients with celiac disease. Clinical Immunology, 264, 110259. https://doi.org/10.1016/j.clim.2024.110259
Hujoel, I. A., & Murray, J. A. (2020). Refractory Celiac Disease. Current Gastroenterology Reports, 22(4), 18. https://doi.org/10.1007/s11894-020-0756-8
Isola, J., Mäki, M., Hils, M., Pasternack, R., Viiri, K., Dotsenko, V., Montonen, T., Zimmermann, T., Mohrbacher, R., Greinwald, R., & Schuppan, D. (2023). The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment. International Journal of Molecular Sciences, 24(13), 10815. https://doi.org/10.3390/ijms241310815
Jamieson, J. A., & Blewett, H. (2025). The Price of Canadian Gluten-Free Staple Foods Remains More than Double and Iron Content Less than Half of Standard Foods in 2024. Plant Foods for Human Nutrition, 80(3), 141. https://doi.org/10.1007/s11130-025-01365-0
Kaufman, B. (2018). Vedolizumab Induction May Prevent Celiac Enteritis After Gluten Challenge in Established Celiac Patients in Histological Remission (Clinical Trial Registration NCT02929316). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT02929316
Lähdeaho, M.-L., Scheinin, M., Vuotikka, P., Taavela, J., Popp, A., Laukkarinen, J., Koffert, J., Koivurova, O.-P., Pesu, M., Kivelä, L., Lovró, Z., Keisala, J., Isola, J., Parnes, J. R., Leon, F., & Mäki, M. (2019). Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: A phase 2a, randomised, double-blind, placebo-controlled study. The Lancet Gastroenterology & Hepatology, 4(12), 948–959. https://doi.org/10.1016/S2468-1253(19)30264-X
Meresse, B., Korneychuk, N., Malamut, G., & Cerf-Bensussan, N. (2015). Interleukin-15, a master piece in the immunological jigsaw of celiac disease. Digestive Diseases (Basel, Switzerland), 33(2), 122–130. https://doi.org/10.1159/000369521
Moreno, M. de L., Rodríguez-Herrera, A., Sousa, C., & Comino, I. (2017). Biomarkers to Monitor Gluten-Free Diet Compliance in Celiac Patients. Nutrients, 9(1), 46. https://doi.org/10.3390/nu9010046
NCT05425446. (n.d.). Retrieved 5 July 2025, from https://svt-cr.dapstudies.com/find-trials/Study/NCT05425446
Okura, Y., Ikawa-Teranishi, Y., Mizoroki, A., Takahashi, N., Tsushima, T., Irie, M., Harfuddin, Z., Miura-Okuda, M., Ito, S., Nakamura, G., Takesue, H., Ozono, Y., Nishihara, M., Yamada, K., Gan, S. W., Hayasaka, A., Ishii, S., Wakabayashi, T., Muraoka, M., … Igawa, T. (2023). Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease. Nature Communications, 14, 8502. https://doi.org/10.1038/s41467-023-44083-4
Patt, Y. S., Lahat, A., David, P., Patt, C., Eyade, R., & Sharif, K. (2023). Unraveling the Immunopathological Landscape of Celiac Disease: A Comprehensive Review. International Journal of Molecular Sciences, 24(20), 15482. https://doi.org/10.3390/ijms242015482
Rodrigo, L., Pérez-Martinez, I., Lauret-Braña, E., & Suárez-González, A. (2018). Descriptive Study of the Different Tools Used to Evaluate the Adherence to a Gluten-Free Diet in Celiac Disease Patients. Nutrients, 10(11), 1777. https://doi.org/10.3390/nu10111777
Rubio-Tapia, A., Hill, I. D., Semrad, C., Kelly, C. P., Greer, K. B., Limketkai, B. N., & Lebwohl, B. (2023). American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. Official Journal of the American College of Gastroenterology | ACG, 118(1), 59. https://doi.org/10.14309/ajg.0000000000002075
Schiepatti, A., Maimaris, S., Nicolardi, M. L., Alimenti, E., Vernero, M., Costetti, M., Costa, S., & Biagi, F. (2022). Determinants and Trends of Adherence to a Gluten-Free Diet in Adult Celiac Patients on a Long-term Follow-up (2000–2020). Clinical Gastroenterology and Hepatology, 20(4), e741–e749. https://doi.org/10.1016/j.cgh.2020.12.015
Schumann, M., Houbiers, J. G., Chvatchko, Y., Mäki, M., Lundin, K. E., Schuppan, D., Vanuytsel, T., Zopf, Y., Deprez, P. H., Hasselblatt, P., Taavela, J., Hoff, D. A., Wahab, P., Isola, J., Tran, I., Guyon-Gellin, N., Holz, J.-B., Vicari, A., & Bouma, G. (2024). 789 CALY-002, AN ANTI-IL-15 ANTIBODY, PREVENTS GLUTEN CHALLENGEINDUCED MUCOSAL DAMAGE AND INFLAMMATION: RESULTS FROM A PHASE 1A/B STUDY. Gastroenterology, 166(5, Supplement), S-194. https://doi.org/10.1016/S0016-5085(24)00940-5
Schuppan, D., Mäki, M., Lundin, K. E. A., Isola, J., Friesing-Sosnik, T., Taavela, J., Popp, A., Koskenpato, J., Langhorst, J., Hovde, Ø., Lähdeaho, M.-L., Fusco, S., Schumann, M., Török, H. P., Kupcinskas, J., Zopf, Y., Lohse, A. W., Scheinin, M., Kull, K., … Greinwald, R. (2021). A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. New England Journal of Medicine, 385(1), 35–45. https://doi.org/10.1056/NEJMoa2032441
Singh, P., Arora, A., Strand, T. A., Leffler, D. A., Catassi, C., Green, P. H., Kelly, C. P., Ahuja, V., & Makharia, G. K. (2018). Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 16(6), 823-836.e2. https://doi.org/10.1016/j.cgh.2017.06.037
Staff, G. E. N. (2013, September 18). GSK Returns Vercirnon Rights to ChemoCentryx after Phase III Flop. GEN - Genetic Engineering and Biotechnology News. https://www.genengnews.com/news/gsk-returns-vercirnon-rights-to-chemocentryx-after-phase-iii-flop/
TEV-CeD2 Study: Do you have celiac disease? Consider joining a clinical trial. (n.d.). TEV-CeD2 Study. Retrieved 5 July 2025, from https://tevstudy.celiac.org/
Views:
381
Downloads:
206
Copyright (c) 2025 Aleksandra Kubas, Aleksander Sobczyk, Aleksandra Górniak, Michał Widawski, Natalia Gizińska, Paulina Lewandowska, Amelia Rusiecka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
